object
tumortr
field
current
use
success
treat
variou
cancer
howev
specif
pathway
associ
efficaci
remain
unknown
immun
respons
evalu
tumortr
fieldsmedi
initi
macrophagespecif
immun
respons
materi
method
subject
raw
mous
macrophag
clinic
relev
level
tumortr
field
vcm
khz
evalu
alter
cytokin
express
releas
well
cell
viabil
addit
investig
statu
immunomodulatori
pathway
determin
role
tumortr
fieldsmedi
immun
activ
result
discuss
result
indic
tumortr
field
treatment
vcm
decreas
cell
viabil
increas
cytokin
messeng
rnaprotein
level
well
level
nitric
oxid
reactiv
oxygen
speci
rel
control
level
tumor
necrosi
factor
interleukin
interleukin
markedli
increas
tumortr
fieldstreat
raw
cell
cocultur
murin
mammari
carcinoma
cell
compar
raw
cell
without
tumortr
field
treatment
moreov
viabil
cell
treat
condit
medium
tumortr
fieldsstimul
raw
cell
decreas
indic
macrophag
activ
tumortr
field
effect
kill
tumor
cell
moreov
tumortr
field
treatment
activ
nuclear
factor
kb
mitogenactiv
protein
kinas
pathway
involv
immunomodulatori
signal
conclus
result
provid
critic
insight
mechan
tumortr
field
affect
macrophagespecif
immun
respons
efficaci
method
cancer
treatment
tumortr
field
ttf
therapi
small
electr
field
puls
skin
disturb
mitosi
repres
noninvas
region
treatment
modal
recent
approv
therapi
recurr
glioblastoma
gbm
us
food
drug
administr
gain
ce
mark
europ
clinic
concept
ttf
therapi
deliv
lowintens
vcm
intermediatefrequ
khz
altern
electr
field
tumor
use
transduc
array
place
skin
around
tumor
site
propos
mechan
action
involv
disrupt
metaphas
tumor
cell
interf
mitot
spindl
format
disrupt
anaphas
dielectrophoret
disloc
intracellular
constitu
result
overal
effect
apoptosi
antimitot
effect
ttf
treatment
show
variou
cell
line
well
gbm
tune
appropri
frequenc
specif
cancer
cell
type
phase
iii
trial
ttf
combin
temozolomid
establish
treatment
protocol
led
minim
toxic
increas
overal
surviv
rate
improv
patient
qualiti
life
equival
therapeut
efficaci
chemotherapi
moreov
addit
combin
chemotherapi
synergist
enhanc
cellular
respons
report
ttf
administ
combin
radiat
therapi
thu
merit
ongo
futur
trial
evalu
ttf
treat
variou
cancer
type
includ
newli
diagnos
gbm
solid
tumor
brain
metastas
nonsmal
cell
lung
cancer
ovarian
cancer
pancreat
cancer
emerg
evid
demonstr
tumor
microenviron
may
greatli
contribut
final
outcom
cancer
treatment
modal
sever
type
cell
includ
leukocyt
fibroblast
vascular
endotheli
cell
form
tumor
microenviron
immun
cell
major
compon
immun
cell
interact
tumor
cell
influenc
initi
prolifer
elimin
invas
metastasi
tumor
particular
tumorassoci
macrophag
immun
cell
orchestr
variou
factor
tumor
microenviron
polar
macrophag
tumorassoci
macrophag
play
crucial
role
link
inflamm
cancer
produc
inflammatori
cytokin
interleukin
il
interferon
g
along
antiinflammatori
mediat
despit
increas
studi
effect
ttf
cancer
influenc
ttf
immun
cell
yet
determin
therefor
understand
mechan
underli
benefici
effect
ttf
therapi
improv
treatment
modal
investig
influenc
ttf
exposur
function
murin
macrophag
raw
cell
frequent
use
vitro
model
investig
immun
respons
inflamm
tumortr
field
gener
use
pair
insul
wire
connect
function
gener
highvoltag
amplifi
gener
sinewav
signal
rang
v
result
appli
electr
field
intens
frequenc
vcm
khz
respect
use
vcm
field
intens
match
applic
clinic
set
irradi
treatment
cell
plate
dish
incub
c
humidifi
condit
atmospher
reach
confluenc
cell
cultur
prepar
condit
medium
raw
mous
macrophag
murin
mammari
carcinoma
cell
purchas
american
type
cultur
collect
manassa
virginia
cultur
dulbecco
modifi
eagl
medium
dmem
welgen
seoul
korea
supplement
heatinactiv
fetal
bovin
serum
fb
antibiot
uml
penicillin
mgml
streptomycin
welgen
c
humidifi
incub
prepar
condit
medium
cm
raw
cell
treat
ngml
lipopolysaccharid
lp
sigma
st
loui
missouri
inflammatori
stimul
control
ttf
nontreat
cell
use
control
group
hour
supernat
harvest
filter
mm
membran
millipor
massachusett
cocultur
raw
cell
cell
cellsml
plate
plate
ttfstreat
raw
cell
ad
well
cocultur
differ
densiti
cellsml
cellsml
cellsml
cell
cocultur
dmem
supplement
fb
antibiot
hour
c
cellfre
supernat
deriv
cocultur
cell
store
c
prior
measur
cytokin
product
amount
invitrogen
carlsbad
california
bd
scienc
san
diego
california
tumor
necrosi
factor
tnfa
r
system
minneapoli
minnesota
produc
cm
determin
commerci
enzymelink
immunoassay
kit
accord
manufactur
protocol
absorb
nm
obtain
use
micropl
reader
thermo
scientif
rockford
illinoi
cell
viabil
determin
trypan
blue
exclus
assay
bromid
mtt
amresco
life
scienc
philadeplhia
pennsylvania
assay
equal
volum
trypan
blue
reagent
ad
cell
suspens
percentag
viabl
cell
evalu
microscopi
cell
plate
plate
cellswel
variou
time
treatment
raw
cell
cm
mtt
mgml
reagent
ad
well
hour
absorb
measur
nm
use
micropl
reader
multiskan
ex
thermo
labsystem
waltham
massachusett
assay
perform
triplic
reactiv
oxygen
speci
ro
level
macrophag
monitor
use
fluoresc
ro
indic
dichlorodihydrofluorescein
diacet
mmoll
molecular
probe
eugen
oregon
cellassoci
fluoresc
detect
fluorescenceactiv
cell
signal
fac
use
facscalibur
flow
cytomet
bd
bioscienc
san
diego
california
flowjo
softwar
v
tree
star
inc
ashland
orogen
imag
fluoresc
cell
acquir
confoc
microscop
carlzeiss
germani
raw
cell
densiti
cellswel
treat
ttf
ngml
lp
escherichia
coli
merck
kgaa
darmstadt
germani
posit
control
activ
macrophag
incub
cultur
supernat
raw
cell
collect
cultur
supernat
mix
amount
griess
reagent
incub
room
temperatur
minut
absorb
mixtur
determin
nm
use
micropl
reader
multiskan
ex
thermo
fisher
scientif
waltham
massachusett
measur
perform
triplic
amount
nitrit
determin
use
standard
curv
establish
total
rna
extract
raw
cell
use
trizol
reagent
invitrogen
revers
transcrib
use
ecodri
premix
clontech
laboratori
mountain
view
california
accord
manufactur
recommend
quantit
revers
transcript
polymeras
chain
reaction
experi
perform
use
maxima
sybr
green
qpcr
master
mix
thermo
scientif
lightcycl
realtim
pcr
system
roch
diagnost
mannheim
germani
use
gapdh
intern
refer
rel
gene
express
calcul
base
ddct
method
follow
primer
pair
use
induc
nitric
oxid
synthas
ino
cga
aac
gct
tca
ctt
cca
forward
tga
gcc
tat
att
gct
gtg
revers
tga
agg
gct
gct
tcc
aaa
cct
ttg
forward
tct
cca
ttg
agg
tgg
aga
gct
ttc
revers
tnfa
atg
agc
aca
gaa
agc
atg
atc
forward
cca
aag
tag
acc
tgc
ccg
gac
revers
gapdh
acc
aca
gtc
cat
gcc
atc
forward
tcc
acc
acc
ctg
ttg
ctg
revers
experi
repeat
least
time
total
protein
raw
cell
extract
tnn
buffer
mm
triscl
ph
mm
nacl
mm
edta
supplement
proteas
inhibitor
mmol
l
phenylmethylsulfonyl
fluorid
pmsf
mgml
aprotinin
mgml
leupeptin
mmoll
na
vo
quantifi
use
bradford
method
protein
sampl
mg
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
transfer
nitrocellulos
membran
block
nonspecif
antibodi
bind
site
membran
incub
overnight
c
mous
monoclon
antibodi
ino
extracellular
signalregul
kinas
erk
phosphoryl
erk
perk
cjun
ntermin
kinas
jnk
pjnk
ikba
pikba
gapdh
incub
peroxidaseconjug
secondari
antibodi
c
hour
protein
band
visual
use
enhanc
chemiluminesc
reagent
ge
healthcar
bioscienc
pittsburgh
pennsylvania
detect
use
amersham
imag
ge
healthcar
bioscienc
rel
level
protein
express
calcul
refer
level
gapdh
result
express
mean
standard
deviat
signific
differ
among
group
determin
analysi
varianc
tukey
post
hoc
comparison
use
graphpad
softwar
version
graphpad
la
jolla
california
statist
signific
defin
p
valu
individu
p
valu
figur
denot
asterisk
p
p
p
investig
effect
ttf
macrophag
raw
cell
treat
ttf
vcm
lp
repres
activ
macrophag
morpholog
chang
observ
phase
contrast
microscop
figur
normal
morpholog
raw
cell
round
control
group
contrast
lpstreat
cell
show
polygon
dendriticlik
morpholog
indic
lp
effect
activ
raw
cell
ttfstreat
cell
dendriticlik
shape
observ
portion
popul
number
cell
seem
decreas
hour
compar
group
therefor
cell
viabil
determin
trypan
blue
dye
exclus
assay
shown
figur
lpsstimul
unstimul
control
cell
continu
prolifer
wherea
raw
cell
treat
ttf
exhibit
cell
growth
inhibit
without
statist
signific
influenc
cell
viabil
nitric
oxid
import
inflammatori
mediat
produc
activ
macrophag
kill
tumor
pathogen
well
convey
intracellular
signal
shown
figur
lpsor
ttfstreat
cell
increas
messeng
rna
mrna
protein
express
ino
compar
control
product
ttfstreat
raw
cell
slightli
increas
wherea
lp
stimul
significantli
enhanc
product
figur
demonstr
activ
macrophag
exhibit
increas
ro
accumul
inflammatori
condit
therefor
evalu
whether
ttf
affect
gener
ro
shown
figur
ro
level
increas
raw
cell
expos
ttf
hour
concomitantli
lpsinduc
ro
gener
also
evid
result
indic
ttf
increas
product
ro
activ
raw
macrophag
among
variou
cytokin
tnfa
activ
macrophag
autocrin
manner
induc
express
inflammatori
immunomodulatori
mediat
raw
cell
treat
ttf
lp
hour
mrna
express
level
proinflammatori
cytokin
tnfa
determin
figur
mrna
level
tnfa
significantli
upregul
administr
ttf
increas
observ
lpsactiv
raw
cell
investig
releas
key
proinflammatori
cytokin
cocultur
medium
compar
group
tnfa
level
cocultur
ttfstreat
raw
cell
cell
significantli
increas
hour
manner
depend
ratio
cell
figur
evalu
cytotox
activ
cm
ttfstreat
raw
cell
cell
mtt
assay
perform
shown
figur
cell
expos
cm
unstimul
raw
cell
show
statist
signific
decreas
viabil
wherea
cell
expos
cm
ttfstreat
raw
cell
exhibit
decreas
viabil
hour
contact
cm
expect
cm
lpstreat
raw
cell
also
significantli
decreas
viabil
cell
result
suggest
ttf
activ
macrophag
promot
express
proinflammatori
cytokin
mitogenactiv
protein
kinas
nuclear
factorkb
signal
pathway
ttfsadminist
raw
cell
investig
signal
pathway
involv
activ
raw
cell
ttf
mitogenactiv
protein
kinas
mapk
nuclear
factorkb
nfkb
signal
pathway
vital
target
regul
inflammatori
respons
examin
use
western
blot
analysi
express
map
kinas
famili
member
name
erk
jnk
mapk
determin
phosphoryl
level
mapk
significantli
increas
ttfsadminist
raw
cell
hour
treatment
howev
activ
mapk
lpstreat
raw
cell
observ
time
point
lp
treatment
activ
raw
cell
quickli
much
strongli
ttf
treatment
normal
cell
condit
nfkb
exist
inact
cytoplasm
complex
inhibitor
ikba
tumortr
fieldsadminist
raw
cell
show
increas
phosphoryl
ikba
indic
subunit
nfkb
releas
ikba
allow
transloc
nucleu
regul
transcript
mani
gene
activ
macrophag
figur
tumortr
field
recent
report
promis
noninvas
therapeut
approach
cancer
therapi
good
clinic
result
underli
mechan
mechan
includ
disrupt
mitosi
select
kill
rapidli
prolifer
cell
deliv
continu
hd
lowintens
intermediatefrequ
altern
electr
field
tumor
site
tumortr
field
ultim
lead
caspasedepend
caspaseindependentinduc
apoptosi
tumortr
field
shown
appli
antimitot
effect
preclin
system
variou
cancer
includ
gbm
similar
molecular
mechan
activ
furthermor
ttf
tri
preclin
system
combin
cytotox
chemotherapeut
agent
order
enhanc
gener
antitumor
effect
combin
treatment
ttf
chemotherapeut
agent
microtubul
inhibitor
nucleosid
analogu
folat
antimetabolit
alkyl
agent
immun
checkpoint
inhibitor
demonstr
addit
cytotox
effect
taxan
ttf
show
synergist
effect
cancer
cell
addit
vitro
preclin
model
ttf
shown
expos
calreticulin
cell
surfac
ultim
significantli
decreas
tumor
volum
vitro
consider
decreas
tumor
volum
combin
antiprogram
tcell
death
significantli
increas
antigenpres
cell
infiltr
tumor
event
show
potenti
immunogen
cell
death
treatment
ttf
need
investig
although
larg
number
studi
use
ttf
anticanc
therapi
ongo
influenc
ttf
normal
tissu
tumor
microenviron
remain
larg
unknown
thu
current
studi
demonstr
ttf
exert
potenti
immunostimulatori
activ
via
regul
nfkbmapk
signal
pathway
raw
macrophag
macrophag
crucial
host
defens
infect
inflammatori
process
releas
molecul
tnfa
basi
result
studi
show
ttf
increas
macrophag
activ
raw
cell
furthermor
ttf
significantli
enhanc
product
raw
cell
vitro
releas
macrophag
act
intracellular
messeng
mediat
nonspecif
immun
respons
also
suggest
critic
factor
immun
respons
nitric
oxid
gaseou
free
radic
act
signal
molecul
biolog
system
recruit
leukocyt
affect
tissu
induc
no
induc
enzym
product
respons
increas
level
accumul
evid
indic
intracellular
ro
also
serv
second
messeng
inflammatori
signal
transduct
modul
releas
inflammatori
mediat
stimul
mapk
activ
result
observ
stimul
raw
cell
ttf
increas
ino
express
well
product
ro
although
increas
much
lower
observ
lpstreat
cell
therefor
ttf
may
immun
mediatingmodul
effect
includ
activ
macrophag
mediat
biolog
function
tumoricid
activ
nodepend
pathway
activ
macrophag
releas
abund
cytokin
act
signal
control
homeostasi
via
regul
cell
differenti
prolifer
apoptosi
immun
respons
figur
upregul
inflammatori
cytokin
ttfstreat
raw
cell
cell
treat
ttf
vcm
lp
ngml
hour
mrna
level
tnfa
evalu
qrtpcr
b
raw
cell
treat
ttf
vcm
hour
cell
cocultur
cell
indic
ratio
ttfsraw
cell
untreatedor
ttfstreat
raw
cell
design
ct
ttf
respect
cocultiv
perform
hour
level
proinflammatori
cytokin
tnfa
determin
elisa
p
p
compar
ttf
group
c
raw
cell
treat
ttf
vcm
lp
ngml
hour
cultur
medium
cm
raw
cell
use
treat
cell
hour
untreat
raw
cell
design
ct
percentag
cell
viabil
determin
mtt
assay
calcul
rel
untreat
cell
none
data
repres
mean
standard
deviat
triplic
sampl
p
p
compar
hour
none
group
yy
p
compar
hour
none
group
elisa
indic
enzymelink
immunoassay
il
interleukin
lp
lipopolysaccharid
mrna
messeng
rna
mtt
bromid
tnf
tumor
necrosi
factor
ttf
tumortr
field
qrtpcr
quantit
revers
transcript
polymeras
chain
reaction
key
cytokin
play
critic
role
immun
inflammatori
process
includ
tnfa
also
produc
tlymphocyt
natur
killer
cell
facilit
releas
activ
macrophag
present
studi
ttf
markedli
treat
raw
cell
releas
tnfa
indic
ttfsstimul
macrophag
contribut
provok
inflammatori
respons
level
tnfa
markedli
higher
ttfstreat
raw
cell
cocultur
murin
mammari
carcinoma
cell
raw
cell
without
ttf
moreov
viabil
cell
treat
cm
ttfsstimul
raw
cell
decreas
indic
macrophag
activ
ttf
effect
kill
tumor
cell
essenti
pathway
inflamm
therefor
evalu
effect
ttf
nfkb
mapk
activ
raw
cell
nuclear
factorkb
ubiquit
transcript
factor
play
crucial
role
inflammatori
process
via
induct
wide
varieti
gene
includ
inflammatori
cytokin
mediat
chemokin
phosphorylationinduc
degrad
ikb
activ
dissoci
nfkb
demonstr
present
result
ttf
significantli
increas
phosphoryl
ikba
raw
cell
therebi
induc
nuclear
transloc
transcript
activ
nfkb
macrophag
moreov
mapk
regul
variou
inflammatori
mediat
includ
tnfa
cyclooxygenas
ino
suggest
inflammatori
activ
ttf
associ
effect
mapk
signal
pathway
key
upstream
signal
pathway
regul
inflammatori
mediat
mitogenactiv
protein
kinas
includ
erk
jnk
particip
activ
nfkb
regul
gene
express
protein
synthesi
inflammatori
mediat
interleukin
major
proinflammatori
cytokin
easili
activ
mapk
pathway
thu
investig
whether
inflammatori
effect
ttf
involv
mapk
regul
inde
mapk
signal
pathway
obvious
activ
ttfstreat
macrophag
therefor
result
indic
ttf
may
increas
inflammatori
respons
induc
mapk
pathway
macrophag
administr
ttf
caus
cell
death
raw
cell
howev
cell
growth
inhibit
clearli
observ
suggest
highli
prolifer
cancer
cell
select
target
ttf
therapi
lipopolysaccharidetr
cell
morpholog
chang
roundshap
dendriticlik
shape
number
cell
figur
activ
raw
cell
via
mapk
nfkb
signal
pathway
raw
cell
treat
ttf
vcm
lp
ngml
hour
level
indic
protein
determin
western
blot
gapdh
use
intern
control
repres
result
independ
experi
shown
b
band
intens
correspond
indic
protein
quantifi
densitometri
use
imag
j
softwar
normal
gapdh
express
foldchang
control
data
repres
mean
standard
deviat
triplic
sampl
p
compar
control
group
lp
indic
lipopolysaccharid
mapk
mitogenactiv
protein
kinas
nfkb
nuclear
factorkb
ttf
tumortr
field
decreas
earli
stage
subsequ
recov
therefor
effect
ttf
variou
type
normal
cell
investig
vivo
assay
also
need
although
studi
extrapol
vivo
condit
may
provid
theoret
experiment
basi
immun
respons
specif
ttf
treatment
futur
conclus
first
result
demonstr
role
mapknfkb
pathway
ttfsinduc
inflammatori
action
raw
cell
clearer
biolog
understand
function
signific
treatment
may
constitut
potenti
new
therapeut
option
thu
result
provid
preclin
basi
ttf
therapi
expand
research
gear
toward
develop
novel
anticanc
modal
author
declar
potenti
conflict
interest
respect
research
authorship
andor
public
articl
author
disclos
receipt
follow
financi
support
research
authorship
andor
public
articl
studi
support
grant
korea
institut
radiolog
medic
scienc
kiram
fund
ministri
scienc
ict
republ
korea
eun
ho
kim
phd
http
